Vivaldi Coelho Rogerio sold $120K of CRNX
Vivaldi Coelho Rogerio sold 3,000 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $40.00 ($0.12M total) on 2026-07-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale of 3,000 shares at $40.00, totaling $120,000, executed under a pre-arranged 10b5-1 plan.
Market read
Primarily a compliance disclosure; any trading impact is likely limited to short-lived sentiment effects.
What to watch
The article provides no context on prior insider sales frequency, total holdings history, or whether other insiders/major holders acted—so sentiment read-through is constrained.
Background
This is an SEC Form 4 insider transaction disclosure for Crinetics Pharmaceuticals (CRNX).
Ticker impact
Crinetics Pharmaceuticals director Vivaldi Coelho Rogerio sold 3,000 shares at $40.00 on 2026-07-02 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4 sale.
The filing is a disclosed open-market sale by a director, explicitly under a pre-arranged 10b5-1 plan, with no accompanying fundamental catalyst or guidance change.
Market effects
None—single-company insider transaction without sector-wide regulatory/clinical implications.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, traders may briefly reprice the stock if the sale size is viewed as unusually large relative to typical director activity.
Key entities
- issuerCrinetics Pharmaceuticals, Inc.
Subject of the Form 4 insider sale disclosure (CRNX).
- insiderVivaldi Coelho Rogerio
Director who sold 3,000 shares under a 10b5-1 plan.
